Patents Examined by Elly-Gerald Stoica
  • Patent number: 11512119
    Abstract: The subject invention pertains to compositions and methods for preparing and using recombinant proteins based on the fungal Coprinus comatus Y3 protein to control plant and animal viruses and microbes, and diagnose, prevent and treat cancers. Methods are disclosed using compositions comprising recombinant Y3 proteins to diagnose, prevent and/or treat cancer diseases based on recombinant Y3 protein interaction with glycans expressed on cancer cells.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 29, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Yousong Ding, Peilan Zhang, Steven Douglas Bruner
  • Patent number: 11504432
    Abstract: The present invention provides the modular design and assembly of novel targeting bio-conjugates, exclusively assembled by means of biotin-biotin binding element conjugation, comprising mono-biotinylated cell binding component, a tetrameric biotin-binding element, and mono-biotinylated payload for therapeutic and diagnostic purposes. In addition, there is provided a method of delivering the payload, such as therapeutic oligonucleotides, via mono-biotinylated targeting devices, such as antibodies or ligands, into eukaryotic cells by means of receptor-mediated endocytosis. The targeting bio-conjugates are suitable for use in the areas of medicine, pharmacy and biomedical research.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 22, 2022
    Assignee: TECHNISCHE UNIVERSITÄT DRESDEN
    Inventor: Achim Temme
  • Patent number: 11498966
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: November 15, 2022
    Assignees: Orionis Biosciences Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • Patent number: 11471532
    Abstract: The present invention relates to inhibitors of the interaction between H. pylori IIopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 18, 2022
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG, DER WISSENSCHAFT EN E.V., TECHNISCHE UNIVERSITÄT MÜNCHEN
    Inventors: Anahita Javaheri, Tobias Kruse, Markus Gerhard, Bernhard B. Singer, Daniel Hornburg, Han Remaut, Matthias Mann, Felix Meissner, Steffen Backert
  • Patent number: 11464869
    Abstract: The invention provides, inter alia, methods of treating a disorder characterized by pathological activity of CD30+ cells, such as in certain solid, hematological and lymphoid cancers, in a non-adult human subject by administering an effective amount of an anti-CD30 ADC (antibody drug conjugate), such as, brentuximab vedotin, to the subject. The invention also provides corresponding kits and articles of manufacture suitable for performing the methods provided by the invention.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: October 11, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Adedigbo Fasanmade
  • Patent number: 11464837
    Abstract: The present disclosure provides for methods, systems, and compositions of nucleic acid and peptide sequences. The present disclosure provides for a nucleic acid sequence encoding two or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, and SEQ ID NO: 41.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: October 11, 2022
    Assignee: Think Therapeutics, Inc.
    Inventors: David Gifford, Brandon Carter
  • Patent number: 11464832
    Abstract: The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-treonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine, and to a composition for sensitizing interferon beta resistant cancer cells comprising cFLIP siRNA as an active ingredient.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 11, 2022
    Assignees: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION, ABION INC.
    Inventors: Young Kee Shin, Tae Eun Kim, Sung Youl Hong, Jun Young Choi, Na Young Kim
  • Patent number: 11458208
    Abstract: The invention relates to antibody fusion proteins. Particularly, the invention relates to antibody fusion proteins for intra-cellular and intra-nucleus drugs delivery. The fusion protein of the invention can be used as a peptide penetration system that specifically binds to various targets for the delivery of effector peptides across a biological barrier.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: October 4, 2022
    Assignee: ASCLEPIUMM TAIWAN CO., LTD
    Inventors: Min-che Chen, Ya-chuan Liu, Po-hao Chang, Ya-ping Tsai, Chun-wei Chen, Pei-yi Lee
  • Patent number: 11452762
    Abstract: The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects. Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 27, 2022
    Assignees: Igisu Co., Ltd.
    Inventor: Kyoko Endo
  • Patent number: 11446401
    Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: September 20, 2022
    Assignee: Fusion Pharmaceuticals Inc.
    Inventors: Eric Steven Burak, Julie Metcalf, Natalie Grinshtein, Meiduo Hu, John Fitzmaurice Valliant
  • Patent number: 11448655
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: September 20, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow
  • Patent number: 11427641
    Abstract: The present disclosure provides compositions and methods for extended release of certain types of antibodies in vivo. It was discovered that such antibodies are able to initiate reversible gelation of hyaluronic acid (HA) by creating a depot that dissociates over time to release the antibody without any impact on its physical and chemical properties as well as its biological activity. As certain tissues and organs, such as eyes, joints and skins, contain HA, local injection of the antibodies to these tissues or organs will result in embedding of the antibody in gel formed from the HA, which becomes a repository of slow-released antibodies. In addition, slow-released formulations can be prepared with antibodies mixed with HA, optionally with other polymers.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: August 30, 2022
    Assignee: AmMax Bio, Inc.
    Inventors: Laman Alani, Chung-Chiang Hsu, Kirk William Johnson
  • Patent number: 11426447
    Abstract: The invention relates to a polypeptide, wherein said polypeptide comprises or consists of an EGF-like domain of a neuregulin protein. The invention more over relates to a nucleic acid encoding for said polypeptide, a gene therapy vector comprising said nucleic acid and genetically modified cells expressing said polypeptide. The invention relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector or said cell for the treatment of tumours of the nervous system, in particular for the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: August 30, 2022
    Assignee: LEIBNIZ-INSTITUT FUR ALTERNSFORSCHUNG—FRITZ-LIPMANN-INSTITUT E.V. (FLI)
    Inventors: Alexander Schulz, Helen Morrison
  • Patent number: 11427646
    Abstract: The invention relates to antibodies against carcinoembryonic antigen (CEA) which have a direct cell growth inhibition activity on tumor cells expressing CEA and to their use for the treatment and diagnosis of cancer.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: August 30, 2022
    Assignee: B CELL DESIGN
    Inventors: Armelle Cuvillier, Gaël Champier
  • Patent number: 11419923
    Abstract: The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: August 23, 2022
    Assignee: In3Bio Ltd.
    Inventors: Keith Alan Charlton, Erik D'Hondt, Daniel T. Verhamme
  • Patent number: 11407832
    Abstract: Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PD-L1, VEGF and Fc receptor simultaneously. Also disclosed are a recombinant antibody containing two recombinant proteins of the disclosure, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of VEGF and/or PD-L1 using the recombinant protein.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: August 9, 2022
    Assignee: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    Inventors: Wenzhi Tian, Song Li
  • Patent number: 11406665
    Abstract: The invention relates to apolypeptide capable of binding to TGF-? for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-?, wherein said polypeptide is capable of inhibiting the interaction of TGF-? with the receptor CLPTM1.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: August 9, 2022
    Assignee: GENAGON THERAPEUTICS AB
    Inventors: Johan Erik Simon Fredriksson, Olof Andries Blokzijl
  • Patent number: 11400086
    Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: August 2, 2022
    Assignee: BeyondSpring Pharmaceuticals, Inc.
    Inventors: Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
  • Patent number: 11401326
    Abstract: Embodiments of the disclosure relate to the use of an IL-17 pathway inhibitor for treating chronic infections caused by one or more HPVs.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 2, 2022
    Assignees: Assistance Publique—Hopitaus De Paris, Universite Paris Diderot—Paris 7
    Inventors: Vincent Descamps, Florence Brunet-Possenti
  • Patent number: 11389544
    Abstract: The present invention provides nanoparticle conjugates incorporating the self-assembling module diphenylalanine (FF) dipeptide into a bioactive moiety. The conjugate self-assembles to form distinct nanometric structures such as nanospheres. The present invention further provides nanoparticles formed by supramolecular co-assembly of the conjugates with a diphenylalanine (FF) dipeptide or analog thereof, to generate bioactive self-assembled nanostructures.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: July 19, 2022
    Assignees: RAMOT AT TEL-AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Talia Shekhter Zehavi, Ehud Gazit, Mor Herman-Oron, Genady Kostenich, Arie Orenstein